Assessment of disease activity in pediatric ulcerative colitis

References

• Levine A, Koletzko S, Turner D, et al. The ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–1898.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-a*-9minosalicylic acid therapy for mildly to moderately active ulcerative colitis. A Randomized Study. N Engl J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–837.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Bmj. 1989;298(6666):82–86.
   PubMed Web of Science ®Google Scholar
• Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.
   PubMed Web of Science ®Google Scholar
• Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11:49–54.
   PubMed Web of Science ®Google Scholar
• De Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004;18(4):9.
   Web of Science ®Google Scholar
• Magro F, Langner C, Driessen A, et al. European Society of Pathology (ESP) and the European Crohn’s and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827–851.
   PubMed Web of Science ®Google Scholar
• Antonioli DA. Pediatric inflammatory bowel disease. Pediatr Dev Pathol. 2005;8:2–19.
   PubMed Web of Science ®Google Scholar
• Najarian RM, Hait EJ, Leichtner AM, et al. Clinical significance of colonic intraepithelial lymphocytosis in a pediatric population. Mod Pathol. 2009;22:13–20.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003;38:348–354.
   PubMed Web of Science ®Google Scholar
• Mäkitalo L, Kolho KL, Karikoski R, et al. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol. 2010;45:862–871.
   PubMed Web of Science ®Google Scholar
• León AJ, Gómez E, Garrote JA, et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm. 2009;2009:580450. doi:10.1155/2009/580450.
   PubMed Web of Science ®Google Scholar
• Ohtani K, Ohtsuka Y, Ikuse T, et al. Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis. Pediatr Int. 2010;52:584–589.
   PubMed Web of Science ®Google Scholar
• Carey R, Jurickova I, Ballard E, et al. Activation of an IL-6: STAT3-dependenttranscriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:446–457.
   PubMed Web of Science ®Google Scholar
• Verdier J, Begue B, Cerf-Bensussan N, et al. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:1260–1266.
   PubMed Web of Science ®Google Scholar
• Hölttä V, Klemetti P, Salo HM, et al. Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;57:287–292.
   PubMed Web of Science ®Google Scholar
• Román J, Planell N, Lozano JJ, et al. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis. 2013;19:221–229.
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–433.
   PubMed Web of Science ®Google Scholar
• Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.
   PubMed Web of Science ®Google Scholar
• Koukos G, Polytarchou C, Kaplan JL, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology. 2013;145:842–852.
   PubMed Web of Science ®Google Scholar
• Koukos G, Polytarchou C, Kaplan JL, et al. A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inflamm Bowel Dis. 2015;21:996–1005.
   PubMed Web of Science ®Google Scholar
• Béres N, Szabó D, Kocsis D, et al. Role of altered expression of miR-146a, miR-155, and miR-122 in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:327–335.
   PubMed Web of Science ®Google Scholar
• Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15(12):1218–1223.
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.
   PubMed Web of Science ®Google Scholar
• Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574–588.
   PubMed Web of Science ®Google Scholar
• Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicenter comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–1212.
   PubMed Web of Science ®Google Scholar
• Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460–1465.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012;18:2018–2025.
   PubMed Web of Science ®Google Scholar
• Hommel KA. Psychosocial and behavioral issues in children and adolescents with IBD: clinical implications. Gastroenterol Hepatol (N Y). 2013;9:189–191.
   PubMedGoogle Scholar
• Mackner LM, Greenley RN, Szigethy E, et al. Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2013;56:449–458.
   PubMed Web of Science ®Google Scholar
• Dotson JL, Crandall WV, Zhang P, et al. Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr. 2015;60:200–204.
   PubMed Web of Science ®Google Scholar
• Turner D, Griffiths AM, Griffiths AM, Mack D, et al. Assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis. 2010;16:651–666.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17:1008–1014.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Colman RJ, Mitchell PD, et al. Agreement between patient- and physician-completed pediatric colitis activity index scores. J Pediatr Gastroenterol Nutr. 2011;52:708–713.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A, et al. Pediatric inflammatory bowel disease collaborative research group. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis. 2009;15:816–822.
   PubMed Web of Science ®Google Scholar
• Haapamäki J, Roine RP, Sintonen H, et al. Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health. 2011;47:832–837.
   PubMed Web of Science ®Google Scholar
• Mason A, Malik S, McMillan M, et al. A prospective longitudinal study of growth and pubertal progress in adolescents with inflammatory bowel disease. Horm Res Pediatr. 2015;83:45–54.
   PubMed Web of Science ®Google Scholar
• Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119:1113–1194.
   PubMed Web of Science ®Google Scholar
• Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child. 2004;89:69–71.
   PubMed Web of Science ®Google Scholar
• Sidoroff M, Karikoski R, Raivio T, et al. High sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol. 2010;21:2901–2906.
   Web of Science ®Google Scholar
• Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis. 2011;5:423–429.
   PubMed Web of Science ®Google Scholar
• Waterman M, Knigth J, Dinani A, et al. Predictors of outcome in ulcerative colitis. Inflamm Bowel Dis. 2015;21:2097–2105.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104:1285–1292.
   PubMed Web of Science ®Google Scholar
• Wine E, Mack DR, Hyams J, et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013;7:916–922.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Fitzgerald JE, Wyzga N, et al. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci. 1994;39:1893–1899.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Valtonen E, Rintamäki H, et al. Soluble urokinase plasminogen activator suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2012;47:951–955.
   PubMed Web of Science ®Google Scholar
• Mäkitalo L, Rintamäki H, Tervahartiala T, et al. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-alpha therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2012;47:785–794.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perlvárez ML, García-Sánchez V, Villar-Pastor CM, et al. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis. 2012;18:1864–1871.
   PubMed Web of Science ®Google Scholar
• Bortoluzzi F, Valentini M, Cernigoi C, et al. DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease. Gut. 1995;36:50–54.
   PubMed Web of Science ®Google Scholar
• Tarlton NJ, Green CM, Lazarus NH, et al. Plasmablast frequency and trafficking receptor expression are altered in pediatric ulcerative colitis. Inflamm Bowel Dis. 2012;18:2381–2391.
   PubMed Web of Science ®Google Scholar
• Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis. Hepatogastroenterology. 1997;44:90–107.
   PubMed Web of Science ®Google Scholar
• Brown KA, Back SJ, Ruchelli ED, et al. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am J Gastroenterol. 2002;97:2603–2608.
   PubMed Web of Science ®Google Scholar
• Polytarchou C, Oikonomopoulos A, Mahurkar S, et al. Assessment of circulating microRNAs for the diagnosis and disease activity evaluation in patients with ulcerative colitis using the nanostring technology. Inflamm Bowel Dis. 2015;21:2533–2539.
   PubMed Web of Science ®Google Scholar
• Chen G, Cao S, Liu F, et al. miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. Biochem J. 2015;471:357–367.
   PubMed Web of Science ®Google Scholar
• Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:414–422.
   PubMed Web of Science ®Google Scholar
• Ma S, St L, As D. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359–366.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.
   PubMed Web of Science ®Google Scholar
• Annaházi A, Molnár T, Farkas K, et al. Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis. 2013;19:316–320.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9 and human beta defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014:29:43–50.
   PubMed Web of Science ®Google Scholar
• Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2012;107:941–949.
   PubMed Web of Science ®Google Scholar
• Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–645.
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Lööf L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414–420.
   PubMed Web of Science ®Google Scholar
• Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–553.
   PubMedGoogle Scholar
• Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894–1899.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol. 2013 Feb 26;2013:179024, Epub. doi:10.1155/2013/179024.
   PubMedGoogle Scholar
• Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229–1235.
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Turner D, Draghi A II, et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1726–1730.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Alfthan H, Hämäläinen E. Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr. 2012;55:751–753.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Jahnsen J. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176–180.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18:756–762.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50–54.
   PubMed Web of Science ®Google Scholar
• Kapel N, Campeotto F, Kalach N, et al. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010;51:542–547.
   PubMed Web of Science ®Google Scholar
• Calafat M, Cabré E, Mañosa M, et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21:1072–1076.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Malmstrøm GH, Skar V, et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51:548–5.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720–725.
   PubMed Web of Science ®Google Scholar
• Heida A, Holtman GA, Lisman-van Leeuwen Y, et al. Avoid endoscopy in children with suspected inflammatory bowel disease who have normal calprotectin levels. J Pediatr Gastroenterol Nutr. 2016;62:47–49.
   PubMed Web of Science ®Google Scholar
• Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNF-α-blocking agents in inflammatory bowel disease patients in deep remission? J Crohn´s Colitis. 2015;9:33–40.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110:921–930.
   PubMed Web of Science ®Google Scholar
• Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer. 2014;134:189–196.
   PubMed Web of Science ®Google Scholar
• Buderus S, Boone J, Lyerly D, et al. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036–1039.
   PubMed Web of Science ®Google Scholar
• Hämäläinen A, Sipponen T, Kolho K-L. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17:5166–5171.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Turner D, Veerman-Wauters G, et al. Rapid test for fecal calprotectin levels in children with Crohn´s disease. J Pediatr Gastroenterol Nutr. 2012;55:436–439.
   PubMed Web of Science ®Google Scholar
• Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:323–330.
   PubMed Web of Science ®Google Scholar
• Heida A, Dijkstra A, Groen H, et al. Comparing the efficacy of a web-assisted calprotextin-based treatment algorithm (IBD_live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials. 2015;16:271. doi:10.1186/s13063-015-0787-x.
   PubMed Web of Science ®Google Scholar
• Gee MS, Harisinghani MG. MRI in patients with inflammatory bowel disease. J Magn Reson Imaging. 2011;33:527–534.
   PubMed Web of Science ®Google Scholar
• Chalian M, Ozturk A, Oliva-Hemker M, et al. MR enterography findings of inflammatory bowel disease in pediatric patients. AJR Am J Roentgenol. 2011;196:W810–6.
   PubMed Web of Science ®Google Scholar
• Giles E, Hanci O, McLean A, et al. Optimal assessment of paediatric IBD with MRI and barium follow-through. J Pediatr Gastroenterol Nutr. 2012;54:758–762.
   PubMed Web of Science ®Google Scholar
• Wallihan DB, Towbin AJ, Denson LA, et al. Inflammatory bowel disease in children and adolescents: assessing the diagnostic performance and inter-reader agreement of magnetic resonance enterography compared to histopathology. Acad Radiol. 2012;19:819–826.
   PubMed Web of Science ®Google Scholar
• Ordás I, Rimola J, García-Bosch O, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut. 2013;62:1566–1572.
   PubMed Web of Science ®Google Scholar
• Sauer CG. Radiation exposure in children with inflammatory bowel disease. Curr Opin Pediatr. 2012;24:621–626.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Hyams JS, Otley A, et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut. 2015;64:438–446.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608.
   PubMed Web of Science ®Google Scholar